Literature DB >> 23409150

Pyrosequencing dried blood spots reveals differences in HIV drug resistance between treatment naïve and experienced patients.

Hezhao Ji1, Yang Li, Binhua Liang, Richard Pilon, Paul MacPherson, Michèle Bergeron, John Kim, Morag Graham, Gary Van Domselaar, Paul Sandstrom, James Brooks.   

Abstract

Dried blood spots (DBS) are an alternative specimen collection format for HIV-1 genotyping. DBS produce HIV genotyping results that are robust and equivalent to plasma when using conventional sequencing methods. However, using tagged, pooled pyrosequencing, we demonstrate that concordance between plasma and DBS is not absolute and varies according to viral load (VL), duration of HIV infection and antiretroviral therapy (ART) status. The plasma/DBS concordance is the highest when VL is ≥5,000 copies/ml and/or the patient has no ART exposure and/or when the duration of HIV infection is ≤2 years. Stepwise regression analysis revealed that VL is most important independent predictor for concordance of DBS with plasma genotypes. This is the first study to use next generation sequencing to identify discordance between DBS and plasma genotypes. Consideration should be given to VL, duration of infection, and ART exposure when interpreting DBS genotypes produced using next generation sequencing. These findings are of particular significance when DBS are to be used for clinical monitoring purposes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23409150      PMCID: PMC3567018          DOI: 10.1371/journal.pone.0056170

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  23 in total

1.  HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania.

Authors:  Asgeir Johannessen; Mona Holberg-Petersen; Gunilla Lövgaarden; Ezra Naman; Vidar Ormaasen; Mecky I Matee; Svein G Gundersen; Johan N Bruun
Journal:  Antivir Ther       Date:  2010

2.  Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance.

Authors:  Xierong Wei; Ae S Youngpairoj; Carolina Garrido; Natalia Zahonero; Angelica Corral; Carmen de Mendoza; Walid Heneine; Jeffrey A Johnson; J Gerardo Garcia-Lerma
Journal:  J Clin Virol       Date:  2010-12-03       Impact factor: 3.168

Review 3.  Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance.

Authors:  Silvia Bertagnolio; Neil T Parkin; Michael Jordan; James Brooks; J Gerardo García-Lerma
Journal:  AIDS Rev       Date:  2010 Oct-Dec       Impact factor: 2.500

4.  High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.

Authors:  Silvina Masciotra; Carolina Garrido; Ae S Youngpairoj; Amanda McNulty; Natalia Zahonero; Angelica Corral; Walid Heneine; Carmen de Mendoza; J Gerardo García-Lerma
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

5.  Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping.

Authors:  Marjorie Monleau; Christelle Butel; Eric Delaporte; Francois Boillot; Martine Peeters
Journal:  J Antimicrob Chemother       Date:  2010-06-11       Impact factor: 5.790

6.  HIV drug resistance surveillance using pooled pyrosequencing.

Authors:  Hezhao Ji; Nathalie Massé; Shaun Tyler; Ben Liang; Yang Li; Harriet Merks; Morag Graham; Paul Sandstrom; James Brooks
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

7.  Evolution of proviral gp120 over the first year of HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Stephen Lagakos; Michaela Herzig; Caitlin Bonney; Lemme Kebaabetswe; Raabya Rossenkhan; David Nkwe; Lauren Margolin; Rosemary Musonda; Sikhulile Moyo; Elias Woldegabriel; Erik van Widenfelt; Joseph Makhema; M Essex
Journal:  Virology       Date:  2008-10-29       Impact factor: 3.616

8.  Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.

Authors:  Annalisa Saracino; Nicola Gianotti; Marianna Marangi; Donatella C Cibelli; Andrea Galli; Grazia Punzi; Laura Monno; Adriano Lazzarin; Gioacchino Angarano
Journal:  J Med Virol       Date:  2008-10       Impact factor: 2.327

9.  Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing.

Authors:  Marjorie Monleau; Céline Montavon; Christian Laurent; Michel Segondy; Brigitte Montes; Eric Delaporte; François Boillot; Martine Peeters
Journal:  J Clin Microbiol       Date:  2009-02-04       Impact factor: 5.948

10.  Accuracy and quality of massively parallel DNA pyrosequencing.

Authors:  Susan M Huse; Julie A Huber; Hilary G Morrison; Mitchell L Sogin; David Mark Welch
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  8 in total

1.  HIV-1 drug resistance genotyping success rates and correlates of Dried-blood spots and plasma specimen genotyping failure in a resource-limited setting.

Authors:  Jonah Omooja; Nicholas Bbosa; Dan Bugembe Lule; Maria Nannyonjo; Sandra Lunkuse; Faridah Nassolo; Stella Esther Nabirye; Hamidah Namagembe Suubi; Pontiano Kaleebu; Deogratius Ssemwanga
Journal:  BMC Infect Dis       Date:  2022-05-17       Impact factor: 3.667

Review 2.  Deep sequencing: becoming a critical tool in clinical virology.

Authors:  Miguel E Quiñones-Mateu; Santiago Avila; Gustavo Reyes-Teran; Miguel A Martinez
Journal:  J Clin Virol       Date:  2014-06-24       Impact factor: 3.168

3.  Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing.

Authors:  Dolly Singh; Adit Dhummakupt; Lilly Siems; Deborah Persaud
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

4.  HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.

Authors:  Rami Kantor; Allison DeLong; Maya Balamane; Leeann Schreier; Robert M Lloyd; Wilfred Injera; Lydia Kamle; Fidelis Mambo; Sarah Muyonga; David Katzenstein; Joseph Hogan; Nathan Buziba; Lameck Diero
Journal:  J Int AIDS Soc       Date:  2014-11-18       Impact factor: 5.396

Review 5.  Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa.

Authors:  Idris Abdullahi Nasir; Anthony Uchenna Emeribe; Iduda Ojeamiren; Hafeez Aderinsayo Adekola
Journal:  Infect Dis (Auckl)       Date:  2017-12-19

6.  Are We Ready for NGS HIV Drug Resistance Testing? The Second "Winnipeg Consensus" Symposium.

Authors:  Hezhao Ji; Paul Sandstrom; Roger Paredes; P Richard Harrigan; Chanson J Brumme; Santiago Avila Rios; Marc Noguera-Julian; Neil Parkin; Rami Kantor
Journal:  Viruses       Date:  2020-05-27       Impact factor: 5.048

Review 7.  Overview of the Analytes Applied in Genotypic HIV Drug Resistance Testing.

Authors:  Hezhao Ji; Paul Sandstrom
Journal:  Pathogens       Date:  2022-06-29

Review 8.  Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations.

Authors:  Santiago Ávila-Ríos; Neil Parkin; Ronald Swanstrom; Roger Paredes; Robert Shafer; Hezhao Ji; Rami Kantor
Journal:  Viruses       Date:  2020-06-05       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.